2 weeks Ago By ABMN Staff
Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) was the target of unusually large options trading activity on Friday. Stock investors bought 53,817 call options on the company. This is an increase of 37% compared to the typical daily volume of 39,409 call options.
Wall Street Analysts Forecast Growth A number of brokerages have weighed in on BMY. Deutsche Bank Aktiengesellschaft decreased their target price on Bristol-Myers Squibb from $53.00 to $45.
00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th.
Jefferies Financial Group boosted their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th.
BMO Capital Markets reissued a “market perform” rating and set a $48.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Finally, TD Cowen upped their target price on Bristol-Myers Squibb from $45.
00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock.
According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $55.00.
Read Our Latest Stock Report on Bristol-Myers Squibb Bristol-Myers Squibb Stock Up 1.6 % Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.
07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43.
Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%.
The company had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion.
During the same quarter in the prior year, the company earned $1.75 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.
7% on a year-over-year basis. Analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.
Bristol-Myers Squibb Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share.
This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.71%.
The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.
Institutional Inflows and Outflows Several large investors have recently made changes to their positions in BMY. ESL Trust Services LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $27,000. LGT Financial Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 42.
7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the period. MFA Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the second quarter worth $39,000.
Fairman Group LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $42,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in shares of Bristol-Myers Squibb in the second quarter valued at approximately $42,000.
76.41% of the stock is owned by institutional investors and hedge funds. About Bristol-Myers Squibb ( Get Free Report ) Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Featured Articles Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.
com's FREE daily email newsletter ..
